Matrubials develops milk-inspired antimicrobial peptides for bacterial infections, with an initial emphasis on women’s health. The company says it addresses antibiotic non-selectivity and emerging antimicrobial resistance by identifying selective peptides from mammalian milk. Its first indication is bacterial vaginosis, while the broader therapeutic concept targets infections across ages and genders.
CEO and co-founder
Co-founder
Co-founder
Co-founder
Matrubials operates in the antibacterial therapeutics market, particularly focusing on women's health issues like Bacterial Vaginosis. Its main competitors include:
Pfizer Inc. - A major player in the pharmaceutical industry, Pfizer offers a range of antibacterial treatments and has significant resources for research and development. Their established market presence and broad product portfolio provide them with a competitive advantage.
Mylan N.V. - Known for its generic medications, Mylan has a strong foothold in the antibacterial market, providing cost-effective alternatives to branded drugs. This can be a notable advantage in price-sensitive markets.
Novartis AG - This Swiss multinational is involved in various therapeutic areas, including infectious diseases. Their extensive research capabilities and global reach allow them to innovate and distribute effectively.
Hikma Pharmaceuticals plc - Focused on generic and branded pharmaceuticals, Hikma has a growing presence in the antibacterial sector, particularly in the U.S. and Middle Eastern markets.
Organon - Specializing in women's health, Organon has a portfolio that includes treatments for bacterial vaginosis, positioning them directly against Matrubials.
Daré Bioscience - This company focuses on women's health and has products aimed at treating bacterial vaginosis, making them a direct competitor.
Symbiomix Therapeutics (Lupin Pharmaceuticals) - They are known for their innovative treatments for bacterial vaginosis, which directly competes with Matrubials' offerings.
Notable differences include Matrubials' unique approach of developing therapeutics derived from milk, which may offer novel mechanisms of action against bacterial infections, potentially addressing antimicrobial resistance more effectively than traditional antibiotics.
Focus on developing therapeutics; revenue from grants and partnerships in healthcare.
Matrubials primarily focuses on the healthcare industry, specifically developing novel antibacterial therapeutics derived from milk to address bacterial infections and antimicrobial resistance, with an initial emphasis on women's health issues such as Bacterial Vaginosis.